Participated · Equity · May 2025

HistoIndex pioneers stain-free, fully automated biophotonic SHG imaging combined with AI-based analysis to visualize and quantify fibrosis for clinical research and pharmaceutical drug development. The company’s core products support fibrosis assessment and precision medicine for metabolic dysfunction-associated steatohepatitis (MASH). HistoIndex recently launched its first Laboratory Developed Test (LDT), FibroSIGHT™, now available for order in the US. The firm intends to expand HistoIndex-partnered laboratories and operations within the US and to develop next-generation AI-powered SHG digital pathology tests for MASH patients. Founded in 2010 and based in Singapore, HistoIndex integrates research from pivotal clinical trials with clinical practice to accelerate drug development and improve patient outcomes. The company says its solutions are used to improve assessment of fibrosis changes and drug efficacy.

Led · Series B · Mar 2024

Biobot Surgical develops minimally invasive robotic systems that target and accurately position biopsy needles to provide comprehensive prostate coverage. Its technology is designed to help physicians detect prostate cancer earlier and to give clinicians confidence to enroll patients in active surveillance programs. The company emphasizes robot-guided biopsy targeting and precise needle placement as its core product capability. The article reports that Biobot Surgical recently completed a financing event. Investors and financial details are limited in the report. No operating metrics or use-of-proceeds details were disclosed in the article. Biobot Surgical is a Singapore-based developer of minimally-invasive robotic diagnostic solutions. The company secured $5.2 million in new investment last month. The capital came from a group of investors. That investor group included a vehicle backed by businessman Tony Tan Choon Keat. The raise also saw participation from long-time backer ZIG Ventures. No additional operating metrics or financial details were provided in the article.

Participated · Series B · Mar 2024

Biobot is a Singapore-based medical robotics company specializing in robotic prostate biopsy and treatment solutions. Its flagship product, the iSR'obot Mona Lisa system, provides urologists with robotic precision and enhanced visualization for percutaneous transperineal procedures. The technology is already in clinical use globally, with more than 50 Mona Lisa robots deployed and over 20,000 procedures completed. Biobot raised $24M in a Series B round led by Mr. Tony Tan, with participation from ZIG Ventures and new strategic investors. The company plans to use the proceeds to expand its presence worldwide and to further develop its digital surgery infrastructure. Biobot is dedicated to redefining the standard of care in urology through technological innovation.